AC Immune Q3: CHF 73.9M Cash, Runway Into Q1 2028, Loss Narrowed to CHF 8.8M
ACIU is trading near its 52-week low of $2.015 (7.2% above the low).
Summary
AC Immune reported Q3 2026 cash resources of CHF 73.9 million, enough to fund operations into Q1 2028, with the quarterly net loss narrowing to CHF 8.8 million from CHF 15.9 million a year earlier.
Key Events · Earnings and Guidance · ACIU
-
Q3 Cash Resources of CHF 73.9M
As of September 30, 2026, cash and cash equivalents stood at CHF 18.7 million, alongside CHF 55.2 million in short-term financial assets — down from CHF 91.4 million at December 31, 2025.
-
Runway Into Q1 2028
Management expects cash resources to fund operations into Q1 2028, excluding potential milestone payments — covering both the year-end 2026 ACI-7104 antibody data and the H1 2027 ACI-19764 Phase 1b readout.
-
Quarterly Loss Narrowed to CHF 8.8M
Net loss for the three months ended September 30, 2026 was CHF 8.8 million versus CHF 15.9 million a year earlier; R&D fell to CHF 9.9 million from CHF 13.1 million and revenue rose to CHF 3.2 million from CHF 0.9 million on Takeda-related recognition.
-
Morphomer Alpha-Synuclein Lead Selected
A lead small-molecule candidate targeting intracellular alpha-synuclein has been nominated and preclinical development initiated, adding a third wholly-owned program behind ACI-7104 and ACI-19764.
Analysis · ACIU · Life Sciences
The quarter's clinical news was already public, but the financials are new and they matter: CHF 73.9 million of cash resources funds operations into Q1 2028, and the quarterly loss nearly halved to CHF 8.8 million from CHF 15.9 million a year ago as R&D spend fell to CHF 9.9 million. Revenue of CHF 3.2 million, up from CHF 0.9 million, came from Takeda-related recognition rather than a new deal. For a clinical-stage company burning roughly CHF 13 million a quarter in operating expenses, that runway removes any near-term financing pressure and keeps the readouts — ACI-7104 antibody characterization before year-end 2026 and ACI-19764 Phase 1b hsCRP data in H1 2027 — fully funded without selling stock.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACIU was trading at $2.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $212.7M. The 52-week trading range was $2.02 to $3.90. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.